High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol for a noninferiority randomized clinical trial

Andrea Cortegiani, Antonino Giarratano, Cesare Gregoretti, Luigi Vetrugno, Uberto Maccari, Maria Rita Taliani, Federico Longhini, Vittoria Comellini, Eugenio Garofalo, Andrea Bruni, Maria Rita Taliani, Paolo Navalesi, Enrico Lupia, Paolo Groff, Annalisa Carlucci, Stefano Nava, Raffaele Scala, Giovanni Misseri

Risultato della ricerca: Articlepeer review

13 Citazioni (Scopus)

Abstract

BackgroundNoninvasive ventilation (NIV) is indicated to treat respiratory acidosis due to exacerbation of chronic obstructive pulmonary disease (COPD). Recent nonrandomized studies also demonstrated some physiological effects of high-flow nasal therapy (HFNT) in COPD patients. We designed a prospective, unblinded, multicenter, randomized controlled trial to assess the noninferiority of HFNT compared to NIV with respect to the reduction of arterial partial pressure of carbon dioxide (PaCO2) in patients with hypercapnic acute respiratory failure with mild-to-moderate respiratory acidosis.MethodsWe will enroll adult patients with acute hypercapnic respiratory failure, as defined by arterial pH between 7.25 and 7.35 and PaCO2 >= 55mmHg. Patients will be randomly assigned 1:1 to receive NIV or HFNT. NIV will be applied through a mask with a dedicated ventilator in pressure support mode. Positive end-expiratory pressure will be set at 3-5 cmH(2)O with inspiratory support to obtain a tidal volume between 6 and 8ml/kg of ideal body weight. HFNT will be initially set at a temperature of 37 degrees C and a flow of 60L/min. At 2 and 6h we will assess arterial blood gases, vital parameters, respiratory rate, treatment intolerance and failure, need for endotracheal intubation, time spent under mechanical ventilation (both invasive and NIV), intensive care unit and hospital length of stay, and hospital mortality.Based on an alpha error of 5% and a beta error of 80%, with a standard deviation for PaCO2 equal to 15mmHg and a noninferiority limit of 10mmHg, we computed a sample size of 56 patients. Considering potential drop-outs and nonparametric analysis, the final computed sample size was 80 patients (40 per group).DiscussionHFNT is more comfortable than NIV in COPD patients recovering from an episode of exacerbation. If HFNT would not be inferior to NIV, HFNT could be considered as an alternative to NIV to treat COPD patients with mild-to-moderate respiratory acidosis.Trial registrationClinicalTrials.gov, NCT03370666. Registered on December 12, 2017.
Lingua originaleEnglish
pagine (da-a)450-457
Numero di pagine8
RivistaTrials
Volume20
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Fingerprint Entra nei temi di ricerca di 'High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol for a noninferiority randomized clinical trial'. Insieme formano una fingerprint unica.

Cita questo